Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 for the Treatment of Glabellar Lines
NCT05248893Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of trenibotulinumtoxinE in glabellar lines, sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Adverse Events, Participants With Post-Baseline Potentially Clinically Important (PCI) Values for Systolic Blood Pressure and 5 more. Started Feb 2022; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05248893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248893.